缬沙坦与氨氯地平对高血压病左室肥厚影响的临床对比研究

Clinical contrast study of anti-hypertensive drug valsartan vs amlodipine in hypertensive patients with left ventricular hypertrophy

目的 用长效钙拮抗剂氨氯地平作对照 ,研究血管紧张素Ⅱ受体拮抗剂缬沙坦对高血压病左室肥厚的影响。方法 6 5例高血压病伴左室肥厚患者分为缬沙坦组 33例和氨氯地平组 32例 ,分别给予缬沙坦 80～ 16 0mg和氨氯地平 5～ 10mg口服 6mon ,疗程结束前后行 2 4hABPM和心脏超声检查。结果两组 2 4hABPM参数 2 4hSBP、2 4hDBP、dSBP、dDBP、nSBP、nDBP和心脏彩色超声参数IVST、PWT、LVMI用药后均较用药前有显著下降 (P <0 .0 1) ;两组治疗后各项指标无显著差异 (P >0 .0 5 )。结论 缬沙坦能够明显降低高血压病伴左室肥厚患者 2 4h血压 ,并能使其左室肥厚明显消退 。

Aim To study clinical efficacy of valsartan,in comparison with amlodipine, in hypertentive patients with left ventricular hypertrophy. Methods 65 hypertentive patients with left ventricular hypertrophy is divided into two groups, with 33 cases in valsartan group and 32 cases in amlodipine group Valsartan 80～160mg and amlodipine 5～ 10 mg were taken by the patients in the two groups for 6 months respectively. 24 h ambulatory blood pressure monitoring ( 24 h ABPM) and color echocardiography were performed in the two groups before and after treatment. Results The parameters of 24 h ABPM ( 24 h SBP? 24 h DBP?dSBP?dDBP?nSBP?nDBP) and color echocardiography (IVST?PWT?LVMI)after treatment in the two groups were significant decreased compared with those before treatment respectively (P<0.01). However, in the parameters after treatment, there was not significant difference between the two groups (P>0.05). Conclusion Valsartan can lower significantly the blood pressure level and make left ventricular hypertrophy remarkably dispelled in hypertensive patients with left ventricular hypertrophy and has the effect similar to that of amlodipine.